The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content:

• Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments
• Pridopidine in Amyotrophic Lateral Sclerosis
• Platform Trials in ALS
• Verdiperstat in Amyotrophic Lateral Sclerosis
• Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis
• CNM-Au8 in Amyotrophic Lateral Sclerosis